{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T02:35:01Z","timestamp":1790303701840,"version":"4.1.0"},"reference-count":114,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"\n \n \n \u00bb Orthopaedic surgeons are increasingly likely to encounter patients with obesity and\/or type 2 diabetes taking glucagon-like peptide-1 (GLP-1) agonists for weight loss.<\/jats:p>\n <\/jats:list-item>\n \n \u00bb GLP-1 agonists are an effective treatment for weight loss with semaglutide and tirzepatide being the most effective agents. Randomized controlled trials using these agents have reported weight loss up to 21 kg (46 lb).<\/jats:p>\n <\/jats:list-item>\n \n \u00bb The use of GLP-1 agonists preoperatively can improve glycemic control, which can potentially reduce the risk of postoperative complications. However, multiple cases of intraoperative aspiration\/regurgitation have been reported, potentially related to the effect of GLP-1 agonists on gastric emptying.<\/jats:p>\n <\/jats:list-item>\n \n \u00bb While efficacious, GLP-1 agonists may not produce sufficient weight loss to achieve body mass index cutoffs for total joint arthroplasty depending on individual patient factors, including starting bodyweight. Multifactorial approaches to weight loss with focus on lifestyle modification in addition to GLP-1 agonists should be considered in such patients.<\/jats:p>\n <\/jats:list-item>\n \n \u00bb Although GLP-1 agonists are efficacious agents for weight loss, they may not be accessible or affordable for all patients. Each patient's unique circumstances should be considered when creating an ideal weight loss plan during optimization efforts.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>","DOI":"10.2106\/jbjs.rvw.23.00167","type":"journal-article","created":{"date-parts":[[2024,1,5]],"date-time":"2024-01-05T14:00:42Z","timestamp":1704463242000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":20,"title":["Glucagon-like Peptide-1 Agonists"],"prefix":"10.2106","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3498-6301","authenticated-orcid":false,"given":"Peter Y.W.","family":"Chan","sequence":"first","affiliation":[{"name":"Department of Orthopaedics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5260-4506","authenticated-orcid":false,"given":"Aleksander P.","family":"Mika","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4125-2154","authenticated-orcid":false,"given":"J. Ryan","family":"Martin","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5044-7084","authenticated-orcid":false,"given":"Jacob M.","family":"Wilson","sequence":"additional","affiliation":[{"name":"Department of Orthopaedics, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,1]]},"reference":[{"issue":"6 suppl 2","key":"r1-20240731","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.arth.2007.04.014","article-title":"The obesity epidemic: its effect on total joint arthroplasty","volume":"22","author":"Fehring","year":"2007","journal-title":"J Arthroplasty"},{"issue":"5","key":"r2-20240731","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.arth.2022.01.087","article-title":"Projected prevalence of obesity in primary total hip arthroplasty: how big will the problem get?","volume":"37","author":"Carender","year":"2022","journal-title":"J Arthroplasty"},{"issue":"24","key":"r3-20240731","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.2106\/JBJS.16.00093","article-title":"Effect of body mass index on reoperation and complications after total knee arthroplasty","volume":"98","author":"Wagner","year":"2016","journal-title":"J Bone Joint Surg Am"},{"issue":"3","key":"r4-20240731","doi-asserted-by":"crossref","first-page":"169","DOI":"10.2106\/JBJS.O.00430","article-title":"Effect of body mass index on complications and reoperations after total hip arthroplasty","volume":"98","author":"Wagner","year":"2016","journal-title":"J Bone Joint Surg Am"},{"issue":"7","key":"r5-20240731","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.arth.2022.03.004","article-title":"What is the impact of body mass index cutoffs on total hip arthroplasty complications?","volume":"37","author":"DeMik","year":"2022","journal-title":"J Arthroplasty"},{"issue":"10031","key":"r6-20240731","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1016\/S0140-6736(16)00271-3","article-title":"Management of obesity","volume":"387","author":"Bray","year":"2016","journal-title":"Lancet"},{"issue":"8","key":"r7-20240731","doi-asserted-by":"crossref","first-page":"bqaa093","DOI":"10.1210\/endocr\/bqaa093","article-title":"A role for GLP-1 in treating hyperphagia and obesity","volume":"161","author":"Grill","year":"2020","journal-title":"Endocrinology"},{"issue":"4","key":"r8-20240731","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/j.arth.2021.12.003","article-title":"Preoperative weight loss and postoperative weight gain independently increase risk for revision after primary total knee arthroplasty","volume":"37","author":"Kim","year":"2022","journal-title":"J Arthroplasty"},{"issue":"6S","key":"r9-20240731","doi-asserted-by":"crossref","first-page":"S165","DOI":"10.1016\/j.arth.2022.02.048","article-title":"Does bariatric surgery prior to primary total knee arthroplasty improve outcomes?","volume":"37","author":"Ryan","year":"2022","journal-title":"J Arthroplasty"},{"issue":"12","key":"r10-20240731","doi-asserted-by":"crossref","first-page":"e214182","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"4","key":"r11-20240731","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab"},{"issue":"3","key":"r12-20240731","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s12325-022-02394-w","article-title":"GLP-1 agonists for weight loss: pharmacology and clinical implications","volume":"40","author":"Moore","year":"2023","journal-title":"Adv Ther"},{"issue":"6","key":"r13-20240731","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1007\/s12325-021-01710-0","article-title":"Weight loss and maintenance related to the mechanism of action of glucagon-like peptide 1 receptor agonists","volume":"38","author":"Ard","year":"2021","journal-title":"Adv Ther"},{"issue":"10321","key":"r14-20240731","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S0140-6736(21)01640-8","article-title":"Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials","volume":"399","author":"Shi","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"r15-20240731","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1080\/00325481.2021.2002616","article-title":"Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice","volume":"134","author":"Wharton","year":"2022","journal-title":"Postgrad Med"},{"issue":"11","key":"r16-20240731","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"issue":"10278","key":"r17-20240731","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/S0140-6736(21)00213-0","article-title":"Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial","volume":"397","author":"Davies","year":"2021","journal-title":"Lancet"},{"issue":"14","key":"r18-20240731","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1001\/jama.2021.1831","article-title":"Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial","volume":"325","author":"Wadden","year":"2021","journal-title":"JAMA"},{"issue":"14","key":"r19-20240731","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1001\/jama.2021.3224","article-title":"Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial","volume":"325","author":"Rubino","year":"2021","journal-title":"JAMA"},{"issue":"10","key":"r20-20240731","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1038\/s41591-022-02026-4","article-title":"Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial","volume":"28","author":"Garvey","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"r21-20240731","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1001\/jama.2021.23619","article-title":"Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes: the STEP 8 randomized clinical trial","volume":"327","author":"Rubino","year":"2022","journal-title":"JAMA"},{"issue":"4","key":"r22-20240731","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-8587(17)30013-X","article-title":"Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial","volume":"5","author":"Sorli","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"r23-20240731","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/S2213-8587(17)30092-X","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial","volume":"5","author":"Ahr\u00e9n","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"r24-20240731","doi-asserted-by":"crossref","first-page":"258","DOI":"10.2337\/dc17-0417","article-title":"Efficacy and safety of once-weekly semaglutide versus exenatide er in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial","volume":"41","author":"Ahmann","year":"2018","journal-title":"Diabetes Care"},{"issue":"5","key":"r25-20240731","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-8587(17)30085-2","article-title":"Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial","volume":"5","author":"Aroda","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"r26-20240731","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1210\/jc.2018-00070","article-title":"Semaglutide added to basal insulin in type 2 diabetes (SUSTAIN 5): a randomized, controlled trial","volume":"103","author":"Rodbard","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"r27-20240731","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"10192","key":"r28-20240731","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"issue":"11","key":"r29-20240731","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S2213-8587(19)30311-0","article-title":"Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial","volume":"7","author":"Lingvay","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"r30-20240731","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/S2213-8587(19)30066-X","article-title":"Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial","volume":"7","author":"Zinman","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"r31-20240731","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.diabet.2019.101117","article-title":"Efficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10)","volume":"46","author":"Capehorn","year":"2020","journal-title":"Diabetes Metab"},{"issue":"9","key":"r32-20240731","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1111\/dom.14765","article-title":"Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): a randomized, open-label, multinational, phase 3b trial","volume":"24","author":"Kellerer","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"r33-20240731","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S2213-8587(21)00174-1","article-title":"Efficacy and safety of once-weekly semaglutide 2.0 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial","volume":"9","author":"Fr\u00edas","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10148","key":"r34-20240731","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0140-6736(18)31773-2","article-title":"Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial","volume":"392","author":"O'Neil","year":"2018","journal-title":"Lancet"},{"issue":"3","key":"r35-20240731","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/dom.14280","article-title":"The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity","volume":"23","author":"Friedrichsen","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"9","key":"r36-20240731","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1111\/dom.12932","article-title":"Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity","volume":"19","author":"Blundell","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"9701","key":"r37-20240731","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1016\/S0140-6736(09)61375-1","article-title":"Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study","volume":"374","author":"Astrup","year":"2009","journal-title":"Lancet"},{"issue":"8","key":"r38-20240731","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1038\/ijo.2016.52","article-title":"Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial","volume":"40","author":"Blackman","year":"2016","journal-title":"Int J Obes (Lond)"},{"issue":"12","key":"r39-20240731","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/S2468-1253(17)30285-6","article-title":"Effects of liraglutide on weight, satiation, and gastric functions in obesity: a randomised, placebo-controlled pilot trial","volume":"2","author":"Halawi","year":"2017","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"r40-20240731","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1411892","article-title":"A randomized, controlled trial of 3.0 mg of liraglutide in weight management","volume":"373","author":"Pi-Sunyer","year":"2015","journal-title":"N Engl J Med"},{"issue":"11","key":"r41-20240731","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ijo.2013.120","article-title":"Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE Maintenance randomized study","volume":"37","author":"Wadden","year":"2013","journal-title":"Int J Obes (Lond)"},{"issue":"3","key":"r42-20240731","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.arth.2017.09.067","article-title":"Postoperative complications of total joint arthroplasty in obese patients stratified by BMI","volume":"33","author":"Zusmanovich","year":"2018","journal-title":"J Arthroplasty"},{"issue":"7","key":"r43-20240731","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1001\/jama.2015.9676","article-title":"Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial","volume":"314","author":"Davies","year":"2015","journal-title":"JAMA"},{"issue":"5","key":"r44-20240731","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.2337\/dc19-1745","article-title":"Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: the SCALE insulin randomized controlled trial","volume":"43","author":"Garvey","year":"2020","journal-title":"Diabetes Care"},{"issue":"3","key":"r45-20240731","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1002\/oby.22726","article-title":"Liraglutide 3.0 mg and intensive behavioral therapy (IBT) for obesity in primary care: the SCALE IBT randomized controlled trial","volume":"28","author":"Wadden","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"10077","key":"r46-20240731","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1016\/S0140-6736(17)30069-7","article-title":"3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial","volume":"389","author":"le Roux","year":"2017","journal-title":"Lancet"},{"issue":"9982","key":"r47-20240731","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/S0140-6736(15)60936-9","article-title":"Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study","volume":"385","author":"Blonde","year":"2015","journal-title":"Lancet"},{"issue":"9951","key":"r48-20240731","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1016\/S0140-6736(14)60976-4","article-title":"Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial","volume":"384","author":"Dungan","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"r49-20240731","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/dom.12634","article-title":"A 24-week study to evaluate the efficacy and safety of once-weekly dulaglutide added on to glimepiride in type 2 diabetes (AWARD-8)","volume":"18","author":"Dungan","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"r50-20240731","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1111\/dom.14469","article-title":"Efficacy and safety of dulaglutide 3.0 and 4.5 mg in patients aged younger than 65 and 65 years or older: post hoc analysis of the AWARD-11 trial","volume":"23","author":"Frias","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"r51-20240731","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.2337\/dc14-1625","article-title":"Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2)","volume":"38","author":"Giorgino","year":"2015","journal-title":"Diabetes Care"},{"issue":"5","key":"r52-20240731","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S2213-8587(18)30023-8","article-title":"Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial","volume":"6","author":"Ludvik","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"7","key":"r53-20240731","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/dom.12937","article-title":"Placebo-controlled, randomized trial of the addition of once-weekly glucagon-like peptide-1 receptor agonist dulaglutide to titrated daily insulin glargine in patients with type 2 diabetes (AWARD-9)","volume":"19","author":"Pozzilli","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"r54-20240731","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"8","key":"r55-20240731","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.2337\/dc13-2759","article-title":"Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3)","volume":"37","author":"Umpierrez","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"r56-20240731","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/dom.12479","article-title":"Safety and efficacy of once-weekly dulaglutide versus sitagliptin after 2 years in metformin-treated patients with type 2 diabetes (AWARD-5): a randomized, phase III study","volume":"17","author":"Weinstock","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"r57-20240731","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"5","key":"r58-20240731","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1210\/jc.2010-2081","article-title":"DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes","volume":"96","author":"Blevins","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9739","key":"r59-20240731","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0140-6736(10)60590-9","article-title":"Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial","volume":"376","author":"Bergenstal","year":"2010","journal-title":"Lancet"},{"issue":"9861","key":"r60-20240731","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(12)61267-7","article-title":"Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study","volume":"381","author":"Buse","year":"2013","journal-title":"Lancet"},{"issue":"8","key":"r61-20240731","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.2337\/dc16-0014","article-title":"Prandial options to advance basal insulin glargine therapy: testing lixisenatide plus basal insulin versus insulin glulisine either as basal-plus or basal-bolus in type 2 diabetes: the GetGoal Duo-2 Trial","volume":"39","author":"Rosenstock","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"r62-20240731","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jdiacomp.2014.01.012","article-title":"Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S)","volume":"28","author":"Rosenstock","year":"2014","journal-title":"J Diabetes Complications"},{"issue":"10","key":"r63-20240731","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.2337\/dc12-2709","article-title":"Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X)","volume":"36","author":"Rosenstock","year":"2013","journal-title":"Diabetes Care"},{"issue":"10402","key":"r64-20240731","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/S0140-6736(23)01200-X","article-title":"Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"402","author":"Garvey","year":"2023","journal-title":"Lancet"},{"issue":"3","key":"r65-20240731","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"7","key":"r66-20240731","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/a-1844-1176","article-title":"The antiobesity effect and safety of GLP-1 receptor agonist in overweight\/obese patients without diabetes: a systematic review and meta-analysis","volume":"54","author":"Guo","year":"2022","journal-title":"Horm Metab Res"},{"issue":"6","key":"r67-20240731","doi-asserted-by":"crossref","first-page":"e13435","DOI":"10.1111\/obr.13435","article-title":"Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials","volume":"23","author":"Iqbal","year":"2022","journal-title":"Obes Rev"},{"key":"r68-20240731","doi-asserted-by":"crossref","first-page":"101213","DOI":"10.1016\/j.eclinm.2021.101213","article-title":"Association of glucagon-like peptide 1 analogs and agonists administered for obesity with weight loss and adverse events: a systematic review and network meta-analysis","volume":"42","author":"Vosoughi","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"3","key":"r69-20240731","doi-asserted-by":"crossref","first-page":"e13543","DOI":"10.1111\/obr.13543","article-title":"Comparative effectiveness of glucagon-like peptide-1 receptor agonists for the management of obesity in adults without diabetes: a network meta-analysis of randomized clinical trials","volume":"24","author":"Alkhezi","year":"2023","journal-title":"Obes Rev"},{"issue":"4","key":"r70-20240731","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.jdiacomp.2016.01.013","article-title":"Gender-related different effects of a combined therapy of Exenatide and Metformin on overweight or obesity patients with type 2 diabetes mellitus","volume":"30","author":"Quan","year":"2016","journal-title":"J Diabetes Complications"},{"issue":"5","key":"r71-20240731","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.diabet.2010.03.009","article-title":"One-year metabolic outcomes in patients with type 2 diabetes treated with exenatide in routine practice","volume":"36","author":"Buysschaert","year":"2010","journal-title":"Diabetes Metab"},{"issue":"5","key":"r72-20240731","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1507\/endocrj.EJ16-0552","article-title":"Analysis of efficacy and safety of dulaglutide 0.75 mg stratified by sex in patients with type 2 diabetes in 2 randomized, controlled phase 3 studies in Japan","volume":"64","author":"Onishi","year":"2017","journal-title":"Endocr J"},{"issue":"11","key":"r73-20240731","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1007\/s40262-016-0410-7","article-title":"Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis","volume":"55","author":"Overgaard","year":"2016","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"r74-20240731","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/00325481.2022.2147326","article-title":"Efficacy and safety of semaglutide for weight management: evidence from the STEP program","volume":"134","author":"Amaro","year":"2022","journal-title":"Postgrad Med"},{"issue":"3","key":"r75-20240731","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/dom.12824","article-title":"Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: a systematic analysis of published clinical trials","volume":"19","author":"Bettge","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"r76-20240731","doi-asserted-by":"crossref","first-page":"102427","DOI":"10.1016\/j.dsx.2022.102427","article-title":"Adverse drug reactions of GLP-1 agonists: a systematic review of case reports","volume":"16","author":"Shetty","year":"2022","journal-title":"Diabetes Metab Syndr"},{"issue":"10","key":"r77-20240731","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"5","key":"r78-20240731","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/dom.12872","article-title":"Upper and\/or lower gastrointestinal adverse events with glucagon-like peptide-1 receptor agonists: Incidence and consequences","volume":"19","author":"Horowitz","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"r79-20240731","doi-asserted-by":"crossref","first-page":"454","DOI":"10.3390\/jpm12030454","article-title":"Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care","volume":"12","author":"Rentzeperi","year":"2022","journal-title":"J Pers Med"},{"issue":"9","key":"r80-20240731","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1111\/dom.13358","article-title":"Exposure-response analysis for evaluation of semaglutide dose levels in type 2 diabetes","volume":"20","author":"Petri","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"r81-20240731","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/jamainternmed.2022.0338","article-title":"Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials","volume":"182","author":"He","year":"2022","journal-title":"JAMA Intern Med"},{"key":"r82-20240731","doi-asserted-by":"crossref","first-page":"g2366","DOI":"10.1136\/bmj.g2366","article-title":"Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies","volume":"348","author":"Li","year":"2014","journal-title":"BMJ"},{"issue":"2","key":"r83-20240731","first-page":"206","article-title":"Pancreatitis and pancreatic cancer in patients with type 2 diabetes treated with glucagon-like peptide-1 receptor agonists: an updated meta-analysis of randomized controlled trials","volume":"48","author":"Nreu","year":"2023","journal-title":"Minerva Endocrinol (Torino)"},{"issue":"5","key":"r84-20240731","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/dom.14640","article-title":"Efficacy and safety of high-dose glucagon-like peptide-1, glucagon-like peptide-1\/glucose-dependent insulinotropic peptide, and glucagon-like peptide-1\/glucagon receptor agonists in type 2 diabetes","volume":"24","author":"De Block","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"r85-20240731","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1001\/jamainternmed.2016.1531","article-title":"Association of bile duct and gallbladder diseases with the use of incretin-based drugs in patients with type 2 diabetes mellitus","volume":"176","author":"Faillie","year":"2016","journal-title":"JAMA Intern Med"},{"issue":"10","key":"r86-20240731","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.2337\/dc19-0415","article-title":"Effects of liraglutide compared with placebo on events of acute gallbladder or biliary disease in patients with type 2 diabetes at high risk for cardiovascular events in the LEADER randomized trial","volume":"42","author":"Nauck","year":"2019","journal-title":"Diabetes Care"},{"issue":"12","key":"r87-20240731","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1097\/00042737-200012120-00015","article-title":"Gallstones in obesity and weight loss","volume":"12","author":"Erlinger","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"r88-20240731","doi-asserted-by":"crossref","first-page":"101076","DOI":"10.1016\/j.artd.2022.101076","article-title":"Dexamethasone is associated with a statistically significant increase in postoperative blood glucose levels following primary total knee arthroplasty","volume":"19","author":"Volkmar","year":"2023","journal-title":"Arthroplast Today"},{"issue":"16","key":"r89-20240731","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2106\/JBJS.17.01316","article-title":"Postoperative blood glucose levels predict infection after total joint arthroplasty","volume":"100","author":"Kheir","year":"2018","journal-title":"J Bone Joint Surg Am"},{"issue":"1","key":"r90-20240731","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s13054-018-2197-4","article-title":"Systematic review of incretin therapy during peri-operative and intensive care","volume":"22","author":"Hulst","year":"2018","journal-title":"Crit Care"},{"issue":"3","key":"r91-20240731","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1053\/j.jvca.2013.06.021","article-title":"Intravenous GLP-1 (7-36) amide for prevention of hyperglycemia during cardiac surgery: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kohl","year":"2014","journal-title":"J Cardiothorac Vasc Anesth"},{"issue":"12","key":"r92-20240731","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1111\/dom.13029","article-title":"Effect of continuous exenatide infusion on cardiac function and peri-operative glucose control in patients undergoing cardiac surgery: a single-blind, randomized controlled trial","volume":"19","author":"Lips","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"r93-20240731","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.amjcard.2007.05.022","article-title":"Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting","volume":"100","author":"Sokos","year":"2007","journal-title":"Am J Cardiol"},{"issue":"8","key":"r94-20240731","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1007\/s12630-023-02521-3","article-title":"Regurgitation under anesthesia in a fasted patient prescribed semaglutide for weight loss: a case report","volume":"70","author":"Gulak","year":"2023","journal-title":"Can J Anaesth"},{"issue":"8","key":"r95-20240731","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1007\/s12630-023-02440-3","article-title":"Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report","volume":"70","author":"Klein","year":"2023","journal-title":"Can J Anaesth"},{"issue":"1","key":"r96-20240731","doi-asserted-by":"crossref","first-page":"zrac169","DOI":"10.1093\/bjsopen\/zrac169","article-title":"Gastroparesis with bezoar formation in patients treated with glucagon-like peptide-1 receptor agonists: potential relevance for bariatric and other gastric surgery","volume":"7","author":"Preda","year":"2023","journal-title":"BJS Open"},{"issue":"7","key":"r97-20240731","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1111\/dom.14373","article-title":"Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes","volume":"23","author":"Dahl","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"r98-20240731","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"r99-20240731","doi-asserted-by":"crossref","first-page":"111091","DOI":"10.1016\/j.jclinane.2023.111091","article-title":"Relationship between perioperative semaglutide use and residual gastric content: a retrospective analysis of patients undergoing elective upper endoscopy","volume":"87","author":"Silveira","year":"2023","journal-title":"J Clin Anesth"},{"issue":"7","key":"r100-20240731","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1007\/s11695-015-1928-8","article-title":"Relationship between bariatric surgery and bone mineral density: a meta-analysis","volume":"26","author":"Ko","year":"2016","journal-title":"Obes Surg"},{"issue":"1","key":"r101-20240731","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s11695-015-1724-5","article-title":"Changes in bone metabolism in morbidly obese patients after bariatric surgery: a meta-analysis","volume":"26","author":"Liu","year":"2016","journal-title":"Obes Surg"},{"key":"r102-20240731","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bone.2016.11.001","article-title":"Changes in bone metabolism after bariatric surgery by gastric bypass or sleeve gastrectomy","volume":"95","author":"Ivaska","year":"2017","journal-title":"Bone"},{"issue":"5","key":"r103-20240731","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1007\/s11695-017-3034-6","article-title":"Bariatric surgery and time to total joint arthroplasty: does it affect readmission and complication rates?","volume":"28","author":"Schwarzkopf","year":"2018","journal-title":"Obes Surg"},{"issue":"11","key":"r104-20240731","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1136\/rapm-2021-102967","article-title":"Bariatric surgery and total knee\/hip arthroplasty: an analysis of the impact of sequence and timing on outcomes","volume":"46","author":"Liu","year":"2021","journal-title":"Reg Anesth Pain Med"},{"issue":"8","key":"r105-20240731","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1016\/j.arth.2021.02.078","article-title":"Surgeon decision-making for individuals with obesity when indicating total joint arthroplasty","volume":"36","author":"Sherman","year":"2021","journal-title":"J Arthroplasty"},{"issue":"4","key":"r106-20240731","doi-asserted-by":"crossref","first-page":"e316","DOI":"10.3928\/01477447-20200521-08","article-title":"Nutritional counseling program for morbidly obese patients enables weight optimization for safe total joint arthroplasty","volume":"43","author":"Lingamfelter","year":"2020","journal-title":"Orthopedics"},{"issue":"5","key":"r107-20240731","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.orcp.2018.06.009","article-title":"Comparison of a patient-centered weight loss program starting before versus after knee replacement: a pilot study","volume":"12","author":"Pellegrini","year":"2018","journal-title":"Obes Res Clin Pract"},{"issue":"1","key":"r108-20240731","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s42836-022-00149-0","article-title":"Obesity and total joint arthroplasty: does weight loss in the preoperative period improve perioperative outcomes?","volume":"4","author":"Laperche","year":"2022","journal-title":"Arthroplasty"},{"key":"r109-20240731","doi-asserted-by":"crossref","DOI":"10.1016\/j.arth.2023.06.023","article-title":"Does preoperative weight loss within 6 months or 1 year change the risk of adverse outcomes in total knee arthroplasty by initial body mass index classification?","author":"Rechenmacher","year":"2023","journal-title":"J Arthroplasty"},{"issue":"12","key":"r110-20240731","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.1097\/CORR.0000000000001017","article-title":"Clinical faceoff: should orthopaedic surgeons have strict BMI cutoffs for performing primary TKA and THA?","volume":"477","author":"Ricciardi","year":"2019","journal-title":"Clin Orthop Relat Res"},{"issue":"12","key":"r111-20240731","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1097\/CORR.0000000000000511","article-title":"Eligibility criteria for lower extremity joint replacement may worsen racial and socioeconomic disparities","volume":"476","author":"Wang","year":"2018","journal-title":"Clin Orthop Relat Res"},{"issue":"6","key":"r112-20240731","doi-asserted-by":"crossref","first-page":"e2317886","DOI":"10.1001\/jamanetworkopen.2023.17886","article-title":"Evaluation of out-of-pocket costs and treatment intensification with an SGLT2 inhibitor or GLP-1 RA in patients with type 2 diabetes and cardiovascular disease","volume":"6","author":"Luo","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"6","key":"r113-20240731","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1002\/oby.23752","article-title":"Liraglutide versus semaglutide for weight reduction-a cost needed to treat analysis","volume":"31","author":"Azuri","year":"2023","journal-title":"Obesity (Silver Spring)"},{"issue":"4","key":"r114-20240731","doi-asserted-by":"crossref","first-page":"321","DOI":"10.2174\/1573399813666170621123227","article-title":"Socioeconomic status: the missing link between obesity and diabetes mellitus?","volume":"14","author":"Volaco","year":"2018","journal-title":"Curr Diabetes Rev"}],"container-title":["JBJS Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.RVW.23.00167","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T13:42:01Z","timestamp":1787751721000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.2106\/JBJS.RVW.23.00167"}},"subtitle":["What the Orthopaedic Surgeon Needs to Know"],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":114,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.2106\/jbjs.rvw.23.00167","relation":{},"ISSN":["2329-9185"],"issn-type":[{"value":"2329-9185","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}